Biomedical Engineering Reference
In-Depth Information
offers the broadest application in almost every area of therapeutics. Thus, these fea-
tures should be sincerely evaluated through specialized distribution of antisense-
oriented research to various respected companies, industries, and institutes. We
request their required collaboration, cooperation, and support of one another in
order to present this long-awaited technology as a practically available therapy to
humankind.
7.14 Acknowledgment
The authors acknowledge financial assistance from All India Council for Technical
Education, and TIFAC CORE in NDDS, Government of India, New Delhi, for pro-
viding research facilities to the team.
References
[1] Zamecnik PC, Stephenson ML. Inhibition of
Rous sarcoma
virus replication and cell trans-
formation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-4.
[2] Cech TR, Zaug AJ, Grabowski PJ.
In vitro
splicing of the ribosomal RNA precursor of
Tetrahymena
: involvement of a guanosine nucleotide in the excision of the intervening
sequence. Cell 1981;27:487-96.
[3] Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and spe-
cific genetic interference by double-stranded RNA in
Caenorhabditis elegans
. Nature
1998;391:806-11.
[4] Roshan R, Ghosh T, Scaria V, Pillai B. MicroRNAs: novel therapeutic targets in neurode-
generative diseases. Drug Discov Today 2009;14:1123-9.
[5] Dowdy S. The future of personalized cancer treatment: an entirely new direction for RNAi
delivery.
http:/
/www.medicalnewstoday.com/articles/150367.php
(accessed December 2009).
[6] Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent
and persistent
in vivo
anti-HBV activity of chemically modified siRNAs. Nat Biotechnol
2005;23:1002-7.
[7] Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronso RT, Knipe DM, et al. An siRNA-
based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006;
439:89-94.
[8] Bitko V, Musiyenko A, Shulyayev O, Barik S. Inhibition of respiratory viruses by nasally
administered siRNA. Nat Med 2005;11:50-5.
[9] MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, Sedliarou I, Wetzel S, Kochar K,
et al. Sequential treatment of drug-resistant tumors with targeted minicells containing
siRNA or a cytotoxic drug. Nat Biotechnol 2009;27:643-51.
[10] Fattal E, Bochot A. Antisense oligonucleotides, aptamers and siRNA: promises for the
treatment of ocular diseases. Arch Soc Esp Oftalmol 2006;81:3-6.
[11] Jeong JH, Mok H, Oh YK, Park TG. siRNA conjugate delivery systems. Bioconjug Chem
2009;20:5-14.
[12] Gao K, Huang L. Nonviral methods for siRNA delivery. Mol Pharm 2008;6:651-8.
[13] Crooke ST. Preliminary studies on genetic engineering: the uptake of oligonucleotides and
RNA by Novikoff Hepatoma Ascites Cells. Houston, TX: Baylor College of Medicine,
School of Graduate Studies; 1972.
Search WWH ::
Custom Search